Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease

J. Pastré, A. Prévotat, C. Tardif, C. Langlois, A. Duhamel and B. Wallaert

Abstract

Background: Adult patients with cystic fibrosis (CF) frequently have reduced exercise tolerance, which is multifactorial but mainly due to bronchial obstruction. The aim of this retrospective analysis was to determine the mechanisms responsible for exercise intolerance in patients with mild-to-moderate or severe disease.

Methods: Cardiopulmonary exercise testing with blood gas analysis at peak exercise was performed in 102 patients aged 28 ± 11 years: 48 patients had severe lung disease (FEV1 < 50%, group 1) and 54 had mild-to-moderate lung disease (FEV1 ≥ 50%, group 2). VO2 peak was measured and correlated with clinical, biological, and functional parameters.

Results: VO2 peak for all patients was 25 ± 9 mL/kg/min (65 ± 21% of the predicted value) and was < 84% of predicted in 82% of patients (100% of group 1, 65% of group 2). VO2 peak was correlated with body mass index, C-reactive protein, FEV1, FVC, RV, DLCO, V̇E/V̇CO2 peak, V̇E/V̇R, PaO2, PaCO2, P(A-a)O2, and breathing reserve. In multivariate analysis, FEV1 and overall hyperventilation during exercise were independent determinants of exercise capacity (R2 = 0.67). FEV1 was the major significant predictor of VO2 peak impairment in group 1, accounting for 31% of VO2 peak alteration, whereas excessive overall hyperventilation (reduced or absent breathing reserve and V̇E/V̇CO2) accounted for 41% of VO2 alteration in group 2.

Conclusion: Exercise limitation in adult patients with CF is largely dependent on FEV1 in patients with severe lung disease and on the magnitude of the ventilatory response to exercise in patients with mild-to-moderate lung disease.

Keywords: Cystic fibrosis, Cardiopulmonary exercise testing, Pulmonary function, Exercise

Background

Cystic fibrosis (CF) is characterized by deterioration of nutritional status and irreversible loss of lung function [1-3]. Patients with CF often experience exertional dyspnea and have reduced maximal exercise capacity, which is an important predictor of mortality [4-7]. Regular exercise in these patients has been associated with improved aerobic exercise endurance and quality of life [4,8]. Physical exercise requires the cardiopulmonary system to deliver oxygen to muscles in sufficient quantity to generate energy through aerobic glycolysis. There are conflicting data on the precise mechanisms underlying exercise intolerance in CF, and a number of factors have been implicated [9], including poor nutritional status, peripheral muscle dysfunction [10,11], and especially, ventilatory limitation [12,13]. In other studies, dysfunctional gas exchange has been shown to play a crucial role in limiting exercise performance [14-17]. Only a third of the variability in exercise capacity of CF patients can be explained by FEV1, demonstrating that resting pulmonary function tests (PFTs) alone are insufficient to explain the exercise limitation [1,9,13]. By comparison, cardiopulmonary exercise testing (CPET) offers a sensitive evaluation of potential physiological disturbances in cardiovascular, respiratory, peripheral, or neurosensory responses to a standardized exercise protocol [18]. Although it remains underutilized in CF [19], CPET could provide important exercise-related
measures that might explain the reduced exercise performance and thus assist in CF patient management aimed at improving exercise capacity.

With this in mind, we initiated a study to determine the mechanisms responsible for exercise limitation in 102 adult CF patients with mild-to moderate or severe lung disease. The patients were subjected to CPET with blood gas analysis during exercise and the results were correlated with clinical and functional characteristics.

Methods

Patients

A total of 102 adult patients (sex ratio M:F 0.52) with CF were enrolled at four CF centers in France: Lille (75 patients), Rouen (15 patients), Dijon (5 patients), and Grenoble (7 patients). Written informed consent for participation in the study was obtained from participants. Use of the patient data was approved by the local ethics committee, and the study was considered observational and approved as such by the Institutional Review Board of the French Learned Society for Pulmonology (Société de Pneumologie de Langue Française, CEPRO 2012 009).

Clinical, nutritional, biological, PFT, and CPET data were obtained on the same day, either at diagnosis or at the routine annual evaluation, and were retrospectively collected. When patients were seen at several follow-up visits, only the data from the first visit were recorded. Hypoxemic patients did not perform CPET and were excluded from the analysis. A diagnosis of CF was obtained by sweat chloride > 60 mmol/L and the presence of CFTR gene mutations by molecular analysis. Additional characteristics recorded at the time of testing were diseases usually associated with CF, bacterial colonization, treatments, and nutritional status, including height and weight measurements and impedance analysis.

Cardiopulmonary testing

Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1 to FVC ratio, total lung capacity (TLC), and residual volume (RV) were measured by plethysmography (Jaeger-Masterlab® cabin). Diffusing capacity of the lung for carbon monoxide (DLCO: mL CO/min/mm Hg) was adjusted for hemoglobin concentration in g/dL according to Cotes’ equation: corrected (Hb) DLCO = DLCO x (10.2 + Hb)/(1.7 x Hb). Following ATS/ERS 2005 guidelines, the lower limits of normal were set at the 5th percentile (or predicted minus 1.64 SD) of each reference population. The results are expressed as percentages of the predicted values. Predicted normal values were derived from standard equations [20–22].

PFTs and CPET were performed in an air-conditioned laboratory (22°C constant temperature), using a standardized protocol as previously described [23,24]. The CPET protocol was the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800°). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range, 8–30 W/min). During exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption (VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT). The oxygen pulse (VO2/HR) was calculated. Measurements of PaO2 and PaCO2 were performed on room air at rest and at peak exercise. Normal values for PaO2 were derived from [25]. Lactatemia was determined at maximal exercise. Breathing reserve (BR) was calculated as BR = (predicted maximum minute ventilation [MMV] – VE peak)/MMV, with MMV estimated from MMV = FEV1 x 40. HR peak was expressed as a percentage of maximum predicted HR, calculated as HR max = 210 – (0.65 x age). Dead space (VD/Vt) was calculated according to Bohr’s equation corrected for the additional instrument dead space: VD/Vt = (PaCO2 – PECO2 mean)/PaCO2 – (Vd [machine]/Vt) where PECO2 is the partial pressure of expired CO2. Predicted values for VO2 max were calculated from reference equations [26]. Poor motivation appeared not to be an interfering factor in our analysis, as all patients had at least one of the following: BR < 15%, peak HR > 90% of predicted, peak lactate > 7 mmol/L, peak exercise PaO2 < 55 mm Hg, and peak VE/VO2 > 35 or peak RER > 1.15 [23]. Immediately after exercise, subjects were asked to score their sense of breathlessness and muscle fatigue at peak exercise using Borg scales.

Statistical analysis

The continuous variables are reported as mean ± SD. Normal distribution of quantitative variables was tested by the Shapiro–Wilk test. Differences in FEV1 between the groups were determined with the Student’s t-test or Mann–Whitney test. Bivariate analyses were performed to study the relationships between each explanatory variable and the VO2 peak. Pearson’s or Spearman’s correlation coefficient was used for quantitative variables, and the Student’s t-test or Mann–Whitney test for qualitative variables. In addition, a multivariable linear regression with a stepwise selection at the level 0.2 was performed to identify a subset of the most important explanatory variables for the relationship with VO2 peak. In order to avoid the problem of multicollinearity which happens when the explanatory variables are highly correlated, and to obtain a parsimonious model, we adopt the
following strategy: first, variables with p < 0.2 were selected and included in a Principal Component Analysis (PCA) in order to study their correlations. Then, the variables included in the multivariable regression model were selected by the results of PCA (graphical correlation circle) on the basis of their clinical pertinence. The stability of the model was assessed by a bootstrap method [27]. The bootstrap resampling method was based on 1000 replicates of the initial dataset. Multivariable regression with a stepwise selection at the level 0.2 was performed on each of these replicates. The inclusion of the variable in the final model was confirmed if this candidate variable was selected in at least 70% of these 1000 analyses. In the final model, for each variable we computed the partial R-square, coefficient, 95% confidence intervals and adjusted p-value. Final variables from the multivariate analysis were applied to each group of FEV1. All analyses were achieved with SAS software version 9.2 (SAS Institute Inc., Cary, NC). All tests were performed at the significant level at 0.05.

Results

Subjects
The demographic and clinical characteristics are shown in Table 1, and the resting PFT results are presented in Table 2. The cohort consisted of 102 CF patients with a mean age of 28 ± 11 years (range 17–67). The time from diagnosis to evaluation was 16 ± 10 years. For data analysis, the cohort was divided into two groups according to their FEV1: group 1 patients with severe lung disease (FEV1 < 50%, 48 patients) and group 2 patients with mild-to-moderate lung disease (FEV1 ≥ 50%, 54 patients). Group 1 had a significantly higher frequency of homozygosity for the CFTR ΔF 508 mutation, pancreatic insufficiency, bronchial colonization with Pseudomonas aeruginosa, and biological inflammatory syndrome, and significantly lower body mass index (BMI) and longer disease duration (data not shown).

The patients had a range of disease severities and were recruited from four centers in France. Patients from different centers all had characteristics consistent with the French CF Registry 2009 Report [28] and showed equivalent frequencies of key CF characteristics (ΔF508 mutation, exocrine pancreatic insufficiency, and colonization with P. aeruginosa), supporting the reproducibility of the results and the potential for extrapolation to other patient populations.

Resting PFT values (Table 2) were significantly more altered in group 1 than in group 2 (Table 2). As expected, three major functional abnormalities were found: obstructive syndrome (FEV1/FVC = 65 ± 15% of predicted), altered distension (RV = 176 ± 65% of predicted), and altered DLCO (68 ± 18% of predicted).

Exercise responses
Exerciser cessation was mainly due to leg fatigue in combination with dyspnea (62%), whereas leg fatigue alone or dyspnea alone was observed in 17% and 21% of patients, respectively. The VO2 peak value (weight-adjusted VO2) was decreased to < 84% of predicted in 83/102 (82%) of patients (48/48 [100%] in group 1 and 35/54 [65%] in group 2) and was significantly lower in group 1 than in group 2 (Table 3).

Analysis of the ventilatory response (VE peak, BR, respiratory rate (RR), V′E/FVC peak) highlighted the differences according to FEV1 impairment (Table 3). Group

| Table 1 Demographic and clinical characteristics of the CF patients |
|---------------------------------|
| ΔF 508 homozygous mutationa     | 31/79 (40%) |
| Smokera                         | 10/102 (10%) |
| Oxygen supplementationa         | 11/95 (11%) |
| ABPAa                           | 33/95 (35%) |
| Exocrine pancreatic insufficiencya | 78/102 (76%) |
| Diabetesa                       | 21/102 (21%) |
| Nasal polyposisa                | 25/94 (27%) |
| BMIA, kg/m2b                    | 20 (20 ± 3) |
| Lean body mass, kgb             | 45 (48 ± 9) |
| Pseudomonas aeruginosab         | 63/99 (63%) |
| Staphylococcus aureus MSa       | 36/99 (36%) |
| Mycobacterium abscessa          | 4/99 (4%) |
| Blood leukocytes, 1012/mm3b     | 9 (9.7 ± 3.8) |
| Blood polymorphonuclear neutrophils, 1012/mm3b | 6 (6.4 ± 3.3) |
| CRP, mg/Lb                      | 5.5 (15 ± 30) |
| Serum albumin, g/Lb             | 42 (42 ± 4) |

| Table 2 Resting pulmonary function tests in CF patients classified according to FEV1 |
|---------------------------------|
| FEV1                           | All patients (n = 102) | Group 1 (n = 48) | Group 2 (n = 54) |
| FEV′1                          | < 50%                   | ≥ 50%            |                   |
| FEV1/FVC                       | 60 ± 28                 | 35 ± 9b          | 82 ± 18           |
| FVCa                           | 75 ± 24                 | 56 ± 14b         | 93 ± 16           |
| FEV1/FVC                       | 65 ± 15                 | 54 ± 11b         | 75 ± 10           |
| RVc                           | 176 ± 65                | 220 ± 50d        | 135 ± 45          |
| DLCOa                         | 68 ± 18                 | 56 ± 13b         | 78 ± 14           |
| PaO2, mm Hg                   | 80 ± 14                 | 71 ± 10b         | 87 ± 12           |
| PaCO2, mm Hg                   | 38 ± 4                  | 38 ± 5           | 37 ± 4            |
| P(A-a)O2, mm Hg               | 29 ± 13                 | 38 ± 8b          | 21 ± 12           |

Results are expressed as mean ± SD percentage of predicted values. bP < .0001 compared with group 2.
I had a lower absolute value of $V_E$ at peak exercise, and a depletion of BR. Hyperventilation was due to simultaneous increases in RR and tidal volume. Impairment in pulmonary gas exchange was more severe in group 1, as shown by higher values of $P(A-a)O_2$, $V_D/V_T$ peak, and $PaCO_2$, and lower values of $PaO_2$. Cardiocirculatory responses were normal in group 2, but patients in group 1 showed low $VO_2/HR$ values and a significant decrease in peak HR. Four patients experienced ECG abnormalities but continued with the exercise test.

**Determinants of exercise capacity**

Significant correlations were observed between $VO_2$ peak and nutritional status (BMI, lean body mass), inflammation markers (C-reactive protein [CRP], leukocytosis), resting PFT (FVC, FEV1, RV, DLCO, P(A-a)O2), and quantifiable parameters of CPET ($V_E$ peak, $V_E/VO_2$ peak, $V_E/VCO_2$ peak, BR, $V_D/V_T$ peak, $PaO_2$ peak, P(A-a)O2 peak, and lactatemia peak), only $FEV_1$, $V_E/VCO_2$ peak, and BR were found to be independent predictors of exercise capacity ($r^2 = 0.67$). Analysis of these three variables showed that, for group 1, 31% of the $VO_2$ peak was explained by $FEV_1$, whereas the major determinants of the $VO_2$ peak in group 2 were BR, $FEV_1$ and $V_E/VCO_2$ peak (Table 5).

Separate analysis in the cohort of Lille (75 out of the 102 patients) showed the same results: $FEV_1$, BR and $V_E/VCO_2$ were independent predictors of exercise capacity ($r^2 = 0.65$) (data not shown).

**Discussion**

Our study focused on a population of 102 adults with CF who underwent CPET with blood gas analysis at peak exercise. Maximal oxygen uptake was impaired in 82% of patients and was more pronounced in patients with low $FEV_1$. We noted a high prevalence of abnormal exercise responses in our population, including abnormal gas exchange, ventilatory and cardiocirculatory

### Table 3 Cardiopulmonary exercise tests in CF patients classified according to $FEV_1$

| All patients (n = 102) | Group 1 (n = 48) | Group 2 (n = 54) |
|------------------------|------------------|------------------|
| $FEV_1$                | < 50%            | 50%              |
| $VO_2$ peak, mL/kg/min | 25 ± 9           | 20 ± 5<sup>a</sup> | 30 ± 8.5<sup>a</sup> |
| $VO_2$ peak*           | 65 ± 21          | 51 ± 13<sup>d</sup> | 77 ± 20<sup>d</sup> |
| Borg dyspnea           | 4.7 ± 1.9        | 5.6 ± 2<sup>b</sup> | 4.1 ± 1.5<sup>b</sup> |
| Borg Leg fatigue       | 4.5 ± 1.8        | 5.2 ± 1.8<sup>b</sup> | 4.4 ± 1.7<sup>b</sup> |
| $VE$ peak, L/min       | 58 ± 22          | 44 ± 11<sup>d</sup> | 70 ± 21<sup>d</sup> |
| RR peak, min           | 41 ± 9           | 43 ± 9<sup>b</sup> | 39 ± 8<sup>b</sup> |
| $V_E/FVC$ peak, %      | 48 ± 11          | 47 ± 13          | 46.8 ± 8 |
| $V_E/VO_2$ peak        | 41 ± 7           | 42 ± 7           | 41 ± 7 |
| $V_E/VCO_2$ peak       | 36 ± 6           | 37 ± 6           | 35 ± 5 |
| BR, %                  | 24 ± 20          | 8 ± 11<sup>d</sup> | 37.5 ± 16<sup>d</sup> |
| $V_O_2/V_T$ peak       | 0.32 ± 0.11      | 0.39 ± 0.07<sup>d</sup> | 0.25 ± 0.10<sup>d</sup> |
| pH peak                | 7.34 ± 0.04      | 7.34 ± 0.04      | 7.35 ± 0.04 |
| $PaO_2$ peak, mm Hg    | 76 ± 16          | 63 ± 10<sup>d</sup> | 89 ± 12<sup>d</sup> |
| $PaCO_2$ peak, mm Hg   | 40 ± 7           | 44 ± 6<sup>d</sup> | 36 ± 4<sup>d</sup> |
| P(A-a)O2 peak, mm Hg   | 37 ± 13          | 46 ± 8<sup>d</sup> | 28 ± 10<sup>d</sup> |
| Lactatemia peak, mmol/L| 7 ± 26           | 6 ± 2<sup>d</sup> | 7.9 ± 3<sup>d</sup> |
| HR peak<sup>a</sup>    | 82 ± 10          | 79 ± 8<sup>d</sup> | 86 ± 9<sup>d</sup> |
| $VO_2/HR$ peak<sup>a</sup> | 79 ± 22          | 67 ± 16<sup>d</sup> | 90 ± 21<sup>d</sup> |

<sup>a</sup>Results are expressed as mean ± SD percentage of predicted values.
<sup>b</sup>p < 0.01 compared with group 2.
<sup>d</sup>p < 0.001 compared with group 2.

### Table 4 Correlation of clinical and functional variables with $VO_2$ peak in CF patients

| Qualitative variables | n | P value |
|-----------------------|---|---------|
| Female                | 102 | .22     |
| $\Delta F508$ homozygous mutation | 79 | .02     |
| Exocrine pancreatic insufficiency | 102 | .55     |
| Pseudomonas aeruginosa | 99 | .36     |

| Quantitative variables | n | Correlation (r) |
|------------------------|---|-----------------|
| Age, years             | 102 | -0.11 .29       |
| BMI, kg/m<sup>2</sup>  | 102 | 0.26 .009       |
| Leukocytosis, 10<sup>9</sup>/mm<sup>3</sup> | 70 | -0.42 .003       |
| CRP, mg/L              | 64  | -0.34 .006      |
| Serum albumin, g/L     | 43  | 0.34 .02        |
| $FEV_1$                | 102 | 0.71 < .0001    |
| $FVC$<sup>*</sup>      | 102 | 0.69 < .0001    |
| $RV$<sup>*</sup>       | 79  | -0.58 < .0001   |
| DLCO<sup>*</sup>       | 68  | 0.56 < .0001    |
| $PaO_2$, mm Hg         | 98  | 0.43 < .0001    |
| $PaCO_2$, mm Hg        | 98  | 0.11 .29        |

| Cardiopulmonary exercise parameters | n | Correlation (r) |
|-------------------------------------|---|-----------------|
| $V_E$ peak, L                       | 102 | 0.64 < .0001    |
| $V_E/VO_2$ peak*                    | 98  | -0.35 < .0001   |
| BR, %                               | 102 | 0.37 < .0001    |
| $V_E/V_T$ peak*                     | 94  | -0.64 < .0001   |
| $PaCO_2$ peak, mm Hg                | 97  | -0.45 < .0001   |
| P(A-a)O2 peak, mm Hg                | 97  | -0.54 < .0001   |
| Lactatemia peak, mmol/L<sup>*</sup> | 86 | 0.59 < .0001    |
| HR peak<sup>a</sup>                 | 102 | 0.40 < .0001    |

<sup>a</sup>Correlations based on percentage of predicted values.
<sup>*</sup>Selected variables for multivariate stepwise analysis.

Pastré et al. BMC Pulmonary Medicine 2014, 14:74
http://www.biomedcentral.com/1471-2466/14/74
responses, and peripheral limitation. The main findings from this study are that exercise intolerance in CF is multifactorial and is correlated mainly with resting pulmonary function, nutritional status, and inflammatory status, but is also affected by the magnitude of the overall ventilatory response during exercise. Multivariate analysis revealed that bronchial obstruction plays a dominant role in patients with severe disease, whereas excessive hyperventilation during exercise was the major determinant of exercise limitation in patients with mild-to-moderate disease.

CF can be associated with abnormal gas exchange, ventilatory, cardiocirculatory, and muscular responses to exercise [3,9,13,29]. In our study, these abnormalities were responsible for limiting the aerobic capacity of 82% of patients, a proportion consistent with previous studies.

Table 5 Determinants of VO₂ peak in CF patients

| Variable          | All patients (n = 102) | Group 1 (n = 48) | Group 2 (n = 54) |
|-------------------|------------------------|-----------------|-----------------|
| FEV₁ %            | 50 (0.84 [0.70;0.98])<sup>a</sup> | 51 (1.06 [0.70;1.45])<sup>a</sup> | 18 (0.67 [0.46;0.98])<sup>a</sup> |
| BR                | 12 (−0.62 [−0.82;−0.42])<sup>a</sup> | 6 (−0.36 [−0.68;−0.04])<sup>b</sup> | 35 (−0.85 [−1.10;−0.59])<sup>a</sup> |
| Vₖ/VECO₂ peak     | 5 (−1.13 [−1.56;−0.69])<sup>a</sup> | 15 (−0.95 [−1.41;−0.48])<sup>c</sup> | 6 (−1.52 [−2.22;−0.82])<sup>a</sup> |

Results are expressed as the partial r-square (r²), i.e. the percentage of VO₂ alteration explained by the variable. Coefficient and 95% confidence intervals are shown between parentheses. FEV₁, Vₖ/VECO₂ peak, and BR were independent predictors explaining 67% of exercise capacity (r² = 0.67). In group 1, 31% of the VO₂ peak was explained by FEV₁, whereas, in group 2, BR was the major determinant explaining 35% of the VO₂ peak.

Results are derived from multivariable analysis.

<sup>a</sup>Adjusted p value < .0001; <sup>b</sup>p = .027; <sup;c</sup>p = .0002.
of adult CF patients [5,12,30]. We did not observe a single exercise profile common to all patients, reflecting the complexity of mechanisms involved in exercise limitation in CF patients. Some patients showed abnormalities predominantly in gas exchange, others in the ventilatory response. Still others experienced exercise intolerance despite the absence of ventilatory limitation. The relative contribution of these factors differed between the two groups.

In our study, BMI and CRP levels were strongly correlated with exercise limitation, which is consistent with several studies indicating the importance of inflammatory and nutritional status in exercise limitation. Nutritional status plays a well-established role in CF exercise intolerance [31] and prognosis [32], and may be linked to the chronic inflammation observed in CF patients, which is mainly due to respiratory colonization [33]. Inflammatory markers such as CRP are also negatively associated with exercise capacity in patients with CF [7]. Moreover, inflammation is experimentally correlated with loss of muscle mass [34] and skeletal muscle weakness [10] and could explain the association observed here between CRP, lean body mass, and reduced maximal oxygen uptake.

Multivariate analysis showed that FEV₁ was the most significant predictor of VO₂ peak in patients with severe lung disease. This result is consistent with data from earlier studies [3,35] and demonstrates the predominant role of ventilatory disorders in exercise limitation in severe CF patients. Additional functional parameters, such as distension, obstruction, and CO diffusion also correlated with VO₂ peak, but were not independent predictors. The low BR exhibited by our population is another characteristic of the exercise response in severe CF patients. Tantisira et al. showed that the BR index (VE/maximal voluntary ventilation calculated at ventilatory threshold) was the most powerful predictor of mortality in CF patients awaiting lung transplantation [36]. This has also been observed in COPD [37] but is not common to all obstructive lung diseases. For example, McNicholl et al. reported that only 18% of severe asthma patients had ventilatory limitation due to obstructive lung function [38].

In contrast, the VO₂ peak was not fully explained by FEV₁ in patients with mild-to-moderate lung disease, and some patients exhibited impaired aerobic capacity despite having normal resting lung function (Figure 1). Indeed, multivariate analysis showed that two CPET parameters were the major independent determinants of VO₂ peak in group 2: hyperventilation due to abnormal ventilatory control, resulting in high ventilatory equivalents (as demonstrated by VE/VO₂ and VE/VCO₂ peaks), and BR depletion. Exercise ventilation is regulated by numerous mechanisms, most of which remain incompletely understood [39]. Hyperventilation during exercise reflects a nonspecific response to one or more dysfunctional links in the respiratory chain, but the main cause is not known [40]. In some diseases, such as heart failure, hyperventilation is recognized as a more relevant prognostic factor than VO₂ peak. The hyperventilatory response may be due to several factors, including inefficient gas exchange as reflected by P(A-a)O₂ and the V₅/O₅ ratio. Although hyperventilation is difficult to relate to other abnormalities, the strong correlation of hyperventilation with oxygen pulse and peak lactatemia suggests that central (cardiovascular) and peripheral (muscle) determinants play a role [10].

In our study, all patients underwent blood gas analysis at peak effort and we noted a high prevalence of gas exchange abnormalities during exercise. It is interesting to note that patients with identical lung function did not show gas exchange abnormalities. This could be explained by an inadequate ventilatory response in some patients or by a high degree of ventilation-perfusion mismatch. Exercise-induced hypoxemia was common in our study and correlated with VO₂ peak, workload, peak Vǝ/V₅, and dyspnea assessed by the Borg scale (results not shown). We found that P(A-a)O₂ correlated well with peak VO₂, highlighting the relevance of this parameter in gas exchange analysis. Other studies have examined impairment of gas exchange during exercise in CF patients. Nixon et al. showed that PₑₚCO₂ > 41 mm Hg at peak exercise is associated with a twofold higher relative risk of mortality [4]. However, PₑₚCO₂ is not a reliable marker for PaCO₂ during exercise and does not allow accurate calculation of dead space [41]. Compared with PFT, CPET with blood gas analysis at peak exercise is better able to assess gas exchange abnormalities and highlight exercise hypoxemia, a recognized prognosis marker, and thus gauge the need for oxygen supplementation.

The primary limitation of our study is its retrospective nature and the possibility of missing data. Peripheral muscle strength was not assessed and might be a significant contributing factor [10]. These results should be confirmed by a prospective study.

Conclusion
In conclusion, exercise limitation in adult patients with CF correlates with respiratory function as well as nutritional and inflammatory status. This limitation is dependent on FEV₁ in patients with severe disease but is mainly affected by the magnitude of the ventilatory response to exercise in patients with mild-to-moderate lung disease. CPET thus contributes to a more comprehensive understanding of exercise limitation and can assist in patient management aimed at improving exercise capacity.
Competition Interests
For each author, no significant competing interest exists with any companies or organisations whose products or services are mentioned in this article. The authors declare that they have no competing interests.

Authors’ Contributions
Conception and design: BW, JP and AP. Analysis and interpretation: BW, JP, AP, CT, CL and AD. Drafting the manuscript for important intellectual content: BW, JP, AP, and CL. All authors read and approved the final manuscript.

Acknowledgments
The authors wish to thank Anne M. O’Rourke for editing of the manuscript. Collaborators (to be referenced in PubMed): T. Perez (Lille), W. l’Enseignement (Lille), Abderrahmane Mammar (Grenoble), J.M. Perruchini (Dijon). J. Bauduin (Dijon).

Author details
1Univerité Lille 2 et Clinique des Maladies Respiratoires, CRCM Hôpital Calmette, CHRU Lille, France. 2Service de Physiologie Respiratoire, CHRU Rouen, France. 3Unité de Biostatistiques, CHRU Lille, France.

Received: 28 June 2013 Accepted: 23 April 2014

References
1. Marcotte JE, Grisdale RK, Levison H, Coates AL, Canny GJ. Multiple factors limit exercise capacity in cystic fibrosis. Pediatr Pulmonol 1988; 2:274–281.
2. Boucher GP, Lands LC, Hay JA, Hornby L. Activity levels and the relationship to lung function and nutritional status in children with cystic fibrosis. Am J Phys Med Rehabil 1997; 76:311–315.
3. Lands LC, Heigenhauser GJ, Jones NL. Analysis of factors limiting maximal exercise performance in cystic fibrosis. Clin Sci 1992; 83:391–397.
4. Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 1992, 327:1785–1788.
5. Moorcroft AJ, Dodd ME, Webb AK. Exercise testing and prognosis in adult cystic fibrosis. Thorax 1997; 52:291–293.
6. Pianosi P, Leblanc J, Almudevar A. Peak oxygen uptake and mortality in children with cystic fibrosis. Thorax 2005, 60:50–54.
7. van de Weert-van Leeuwen PB, Slieker MG, Hulzebos HJ, Kruitwagen CLJJ, van der Ent CK, Arets HGM. Chronic infection and inflammation affect exercise capacity in cystic fibrosis. Eur Respir J 2012, 39:893–898.
8. Bilto D, Dodd ME, Aabot JV, Webb AK. The benefits of exercise combined with physiotherapy in the treatment of adults with cystic fibrosis. Respir Med 1992, 86:507–511.
9. Almajed A, Lands LC. The evolution of exercise capacity and its limiting factors in Cystic Fibrosis. Paediatr Respir Rev 2012, 13:195–199.
10. Troosters T, Langer D, Vrijens B, Segers J, Wouters K, Janssens W, Gosselink R, Decramer M, Dupont L. Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis. Eur Respir J 2009, 33:99–106.
11. Selvadoral HC, Allen J, Sachinwalla T, Macaulay J, Blakie GC, Van Asperen PP. Muscle function and resting energy expenditure in female athletes with cystic fibrosis. Am J Respir Crit Care Med 2003, 168:1476–1480.
12. Cerny FJ, Pullano TP, Crop GJ. Cardiorespiratory adaptations to exercise in cystic fibrosis. Am Rev Respir Dis 1982, 126:217–220.
13. Shah AR, Goaz D, Keens TG. Determinants of aerobic and anaerobic exercise performance in cystic fibrosis. Am J Respir Crit Care Med 1998, 157:145–150.
14. Lebecque P, Lapierre JG, Lamarre A, Coates AL. Diffusion capacity and oxygen desaturation effects on exercise in patients with cystic fibrosis. Chest 1987, 91:693–697.
15. Bradley S, Solin P, Wilson J, Johns D, Walters EH, Naughton MT. Hypoxemia and hypercapnia during exercise and sleep in patients with cystic fibrosis. Chest 1999, 116:647–654.
16. Mckone EF, Barry SC, Fitzgerald MK, Gallagher CG. Role of arterial hypoxemia and pulmonary mechanics in exercise limitation in adults with cystic fibrosis. J Appl Physiol 2005, 99:1012–1018.
17. Marcus CL, Bader D, Stabile MW, Wang Q, Osher AB, Keens TG. Supplemental oxygen and exercise performance in patients with cystic fibrosis with severe pulmonary disease. Chest 1992, 101:52–57.
18. ATS/ACCP. Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003, 167:211–277.
19. Stevens D, Oates PJ, Armstrong N, Williams CA. A survey of exercise testing and training in UK cystic fibrosis clinics. J Cyst Fibros 2010, 9:302–306.
20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegí G, Wanger J. Standardisation of spirometry. Eur Respir J 2005, 26:319–338.
21. MacIntyre N, Crapo RO, Viegí G, Johnson DC, van der Grinten CPM, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pellegrino R, Wanger J. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005, 26:720–735.
22. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson D, MacIntyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegí G. Standardisation of the measurement of lung volumes. Eur Respir J 2005, 26:511–522.
23. Aguilaniu B, Richard R, Costs F, Bart F, Martinat Y, Stach B, Aguillanu B, Richard R, Costs F, Bart F, Martinat Y, Stach B, Denjean A. Scientific Council of the French Lung Society. [Cardiopulmonary exercise testing]. Rev Mal Respir 2007, 24:2511–2516.
24. Wallaert B, Taleau C, Wenneu-Sternivou L, Duhamel A, Robin S, Aguilaniu B. Reduction of maximal oxygen uptake in sarcoidosis: relationship with disease severity. Respiration 2011, 82:501–508.
25. Sorbini CA, Grassi V, Sollais E, Mueslan G. Arterial oxygen tension in relation to age in healthy subjects. Respiration 1968, 25:3–13.
26. Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. Am Rev Respir Dis 1984, 129:549–555.
27. Suarezri M. The Use of Resampling Methods to Simplify Regression Models in Medical Statistics. Journal of the Royal Statistical Society: Series C (Applied Statistics) 1999, 48:313–329.
28. Vaincre La Mucoviscidose. http://www.vaincrelamuco.org/. 2011 Rapport annuel. 2012.
29. Leroy S, Perez T, Neviere R, Aguillanu B, Wallaert B. Determinants of dyspnea and alveolar hypoventilation during exercise in cystic fibrosis: impact of inspiratory muscle endurance. J Cyst Fibros 2011, 10:159–165.
30. Godfrey S, Mearns M. Pulmonary function and response to exercise in cystic fibrosis. Arch Dis Child 1971, 46:144–151.
31. Gilmans VA, de Meer K, Brackett HJ, Holders PJ. Maximal work capacity in relation to nutritional status in children with cystic fibrosis. Eur Respir J 1990, 5:190–214.
32. Nguyen S, Leroy S, Cracowski C, Perez T, Valette M, Neviere R, Aguilaniu B, Wallaert B. Prognostic value of clinical exercise testing in adult patients with cystic fibrosis. Rev Mal Respir 2010, 27:219–225.
33. Van de Weert-van Leeuwen PB, Arets HGM, van der Ent CK, Beekman JM. Infection, inflammation and exercise in cystic fibrosis. Respir Res 2013, 14:32.
34. Van Heeckeren AM, Tscheikuna J, Walenga RW, Konstan MW, Davis PB, Erolwu B, Hashiu MA, Ferdel TW. Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. Am J Respir Crit Care Med 2000, 161:271–279.
35. Klijn PHC, van der Net J, Kimpen JLH, Holders PJM, van der Ent CK. Longitudinal determinants of peak aerobic performance in children with cystic fibrosis. Chest 2003, 124:2215–2219.
36. Tantisira KG, Systrom DM, Ginns LC. An elevated breathing reserve index at the lactate threshold is a predictor of mortality in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2002, 165:1629–1633.
37. Medoff BO, Oelberg DA, Kanarek DJ, Systrom DM. Breathing reserve at the lactate threshold to differentiate a pulmonary mechanical from cardiovascular limit to exercise. Chest 1998, 113:913–918.
38. McNicholl DM, Megarry J, McCarver LP, Riley MS, Heaney LG. The utility of cardiopulmonary exercise testing in difficult asthma. Chest 2011, 139:1117–1123.
39. Dempsey JA. Challenges for future research in exercise physiology as applied to the respiratory system. Exerc Sport Sci Rev 2006, 34:52–98.
40. Péronnet F, Aguilaniu B: Lactic acid buffering, nonmetabolic CO2 and exercise hyperventilation: a critical reappraisal. *Respir Physiol Neurobiol* 2006, 150:4–18.

41. Lewis DA, Sietsema KE, Casaburi R, Sue DY: Inaccuracy of noninvasive estimates of VD/VT in clinical exercise testing. *Chest* 1994, 106:1476–1480.

doi:10.1186/1471-2466-14-74
Cite this article as: Pastré et al.: Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease. *BMC Pulmonary Medicine* 2014 14:74.